The Journal of Steroid Biochemistry and Molecular Biology
Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors
References (14)
Derivation and properties of Michaelis-Menten and Hill type equations for reference ligands
J. Theoret. Biol.
(1976)- et al.
Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase)
J. Steroid Biochem. Molec. Biol.
(1994) - et al.
Inhibition of 17α-hydroxylase/C17–C20 lyase by bifluranol and its analogues
J. Steroid Biochem.
(1989) Comparative studies on the effects of aminoglutethimide on hamster and rat adrenal cortex
Exp. Toxic. Pathol.
(1992)- et al.
Incidence of prostate cancer will double by the year 2030: the argument for
Eur. Urol.
(1996) Incidence of prostate cancer will double by the year 2030: the argument against
Eur. Urol.
(1996)- et al.
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
N. Engl. J. Med.
(1989)
Cited by (34)
Castration-resistant prostate cancer: From new pathophysiology to new treatment
2014, European UrologyCitation Excerpt :This leads to a secondary rise in adrenocorticotropic hormone and excess mineralocorticoids. To prevent this, AA is coadministered with prednisone 5 mg twice daily [8–10]. In phase 1 and 2 studies there were no dose-limiting toxicities (DLTs) associated with AA, and the main side effects were hypokalemia and lower-limb edema (due to excess mineralocorticoids).
The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer
2013, Cancer Drug Design and Discovery: Second EditionNew treatment options for patients with metastatic castration-resistant prostate cancer
2012, Cancer Treatment ReviewsCitation Excerpt :The combination of cabazitaxel and prednisone has been approved by health authorities around the world, including the European Union, Canada, South Korea, and many countries in South America and approval is pending in numerous other countries. Abiraterone is an oral agent that inhibits cytochrome P450 (CYP) 17, thus blocking androgen production in the testes, prostate, and adrenal glands.22–24 In October 2010, the interim results of the global Phase III trial (COU-AA-301) in patients who had received prior docetaxel were reported at the European Society for Medical Oncology meeting and were later published.
At the crossroads of steroid hormone biosynthesis: The role, substrate specificity and evolutionary development of CYP17
2011, Biochimica et Biophysica Acta - Proteins and ProteomicsCitation Excerpt :The novel CYP17A1 inhibitor, abiraterone acetate (a pregnenolone-derived compound), was developed as a mechanism-based steroidal inhibitor. The features that set it apart from the other candidates are the 3-pyridyl substituent and a double bond between positions C16 and C17 of the steroidal skeleton (these result in both potency and selectivity), which makes this compound a good CYP17A1 inhibitor (Kiapp of < 1 nM) [42,43]. Investigation of mechanisms of action of CYP17A1 inhibitors is an important task not only for anticancer drug discovery but also for screening of compounds with endocrine disrupting activities.
Abiraterone in metastatic prostate cancer without previous chemotherapy
2013, New England Journal of MedicineAbiraterone and increased survival in metastatic prostate cancer
2011, New England Journal of Medicine